Gronkowski Ready to ‘Gronk Spike’ CBD Market With New CBDMEDIC Business Deal
Multiple Injuries and First-Hand Experience with Abacus CEO Convinced Gronk to Hop on CBD Bandwagon
Former New England Patriot and 3 time Super Bowl champ Rob Gronkowski is taking his talents to the CBD industry following his retirement from the National Football League (NFL) last year. Gronk left the NFL at the top of his game after winning Super Bowl LIII last year. Many pro football pundits widely regard Gronkowski as one of the best tight ends of all time. Unfortunately, due to many injuries and multiple surgeries, Gronk made the tough decision to walk away from the game he loves.
You may look at Gronk and see a somewhat goofy frat boy but in reality, the 5-time pro bowler was one of the most financially responsible players to ever play the game. It is a well-known fact that Gronkowski lived off the money he earned from his endorsements while banking every cent of his NFL salary. Over his nine-year NFL career, the 2010 2nd round pick earned more than $54 million during his time in the NFL. It’s safe to say Gronk and his family are set for life.
During those nine years, Gronkowski secured endorsements with some of the largest brands in the world which included Nike, Dunkin’ Donuts, Visa, T-Mobile, Tide, JetBlue, Cheerios, Bodyarmor, DraftKings and Kids Footlocker. Gronk’s larger than life personality made him a marketer’s dream and he is now taking that charisma and enthusiasm to the CBD industry where he will focus his attention on his new role as the pitchman for CBDMEDIC.
CBDMEDIC is owned by Abacus Health Products and describes itself as “a revolutionary line of topical pain and skincare medications developed to provide safe, natural, and temporary relief. CBDMEDIC products are the result of rigorous scientific research and an extensive understanding of natural oils, analgesic ingredients, and how our bodies react to these combinations.”
Currently, the company is offering topical CBD products for Pain Relief and Skincare. CBDMEDIC’s line of pain relief products provides consumers with many choices such as its Active Sport Pain Relief Stick, Muscle & Joint Pain Relief Spray and Back & Neck Pain Relief Ointment.
The variety of options and application methods will appeal to a wide range of customers and the price points on these products appear very reasonable. With Gronk’s background in the NFL and his long history battling injuries, you can tell immediately that he was very involved in the creation of these products.
“As you know, because of my NFL career for nine years, I’m out there in the public. It’s my role to educate people on CBD because I know the research, I know it works,” stated Gronkowski.
“I want to be clear to my fans … I was not in a good place. Football was bringing me down.”
–Rob Gronkowski on his decision to retire pic.twitter.com/zEek2QNPjH
— NFL on ESPN (@ESPNNFL) August 27, 2019
“I threw it on my toes and I swear, it took away the pain I was having. After about five to six hours it wore off a little bit, but I threw it on again. It was wonderful,” said Gronkowski to the Financial Post regarding a toe injury he suffered this past summer.
The proof was in the pudding and this first-hand experience with CBD helped propel Gronk onto the CBD bandwagon.
Gronkowski was in Canada this past week and made several media appearances including a sit-down interview with the Midas Letter podcast in Toronto. Check out the Midas Letter interview below.
Video source: Midas Letter YouTube
Investing in Gronk
For those investors interested in owning a piece of the Gronk deal, Abacus Health Products (CSE: ABCS) (OTCQX: ABAHF) is the maker of CBDMEDIC and its shares trade in Canada on the CSE and the OTCQX in the U.S. Perry Antelman is the CEO of Abacus Health and is the man responsible for signing Gronk to the team.
“There’s a lot of science and research that Perry showed me. That’s what made me believe it. That’s a big factor in representing it too, and advocating (for it),” said Gronkowski.
Antelman anticipates Gronk’s connection to the NFL and his endorsement of CBDMEDIC will help put the company’s topical CBD products in front of millions of new athletes and consumers.
“We’ve been blessed. He’s authentic. You know it’s funny because we had kind of thought in the past … you know who experiences pain? Pro-athletes. No one knows pain like Rob,” stated Antelman.
CBD in the NFL
At this time, there is currently no specific CBD policy in NFL but the league’s rule banning any type of cannabis-derived product will make the use of CBD a risky move by players.
With the NFL’s concussion and prescription opioids problem becoming more evident the need for players to have the option to use a safe product such as CBD has never been greater. The pressure is on the NFL to make changes to its drug policy similar to what the UFC is doing with Aurora Cannabis (TSX: ACB) (NYSE: ACB) to study the science behind CBD and its effects on athletes.
Another pair of retired NFL legends in Calvin Johnson and Robert Sims have also joined the fight against concussions and heavy-duty painkillers. The duo’s business venture, Primative Cannabis has partnered with Harvard University to study the benefits of cannabis as a treatment for Chronic Traumatic Encephalopathy otherwise known as CTE.
Abacus Stock Betting on Gronk
Shares of Abacus Health saw a modest boost when the Gronk deal was first announced in late August. Since then the share price has declined but the drop in price has little to do with Gronk or Abacus and more to do with overall poor market conditions. Once the market stabilizes and the tide begins to rise again it will be interesting to see if Gronk’s impact on the company will translate into a higher share price for investors.
Gronkowski has plenty of skin in the game as he currently holds 302,835 shares of Abacus Health Products at an average price of USD $15 which he obtained as part of his deal with the company.
The former NFL all-star has a massive social media presence which will be a huge asset to Abacus’ marketing strategy. Gronk’s organic online reach will allow CBDMEDIC to reach millions of consumers with the push of a button.
The Cannabis Investor wishes Gronk the best of luck with his CBD business endeavours.
Shares of ABCS closed trading today at CDN $5.85 per share, down 6.4% on the day.
Video source: NFL Throwback YouTube
Move Over Curaleaf, There’s a New MSO in Town and it’s Set to Hit The Street Soon
Get the full details here so you don’t miss out on the next potential 10 bagger.